{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T23:03:14Z","timestamp":1775948594821,"version":"3.50.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite major advances in prevention and medical therapy, heart failure (HF) remains associated\u00a0with high morbidity and mortality, especially in older and frailer patients. Therefore, a\u00a0complete, guideline-based treatment is essential, even in HF patients with conditions\u00a0traditionally associated with a problematic initiation and escalation of the medical HF\u00a0therapy, such as chronic kidney disease and arterial hypotension, as the potential adverse effects are\u00a0overcome by the overall decrease of the absolute risk. Furthermore, since the latest\u00a0data suggest that the benefit of a combined medical therapy (MRA, ARNI, SGLT2i,\u00a0beta-blocker) may extend up to a LVEF of 65%, further trials on these subgroups of\u00a0patients (HFmrEF, HFpEF) are needed to re-evaluate the guideline-directed medical\u00a0therapy across the HF spectrum. In particular, the use of SGLT2i was recently\u00a0extended to HFpEF patients, as evidenced by the DELIVER and EMPEROR-preserved\u00a0trials. Moreover, the indication for other conservative treatments in HF patients, such\u00a0as the intravenous iron supplementation, was accordingly strengthened in the latest\u00a0guidelines. Finally, the possible implementation of newer substances, such as finerenone, in guideline-directed medical practice for HF is anticipated with great interest.<\/jats:p>","DOI":"10.1007\/s10741-024-10389-8","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T13:02:54Z","timestamp":1707829374000},"page":"675-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Latest pharmaceutical approaches across the spectrum of heart failure"],"prefix":"10.1007","volume":"29","author":[{"given":"Dimitrios","family":"Bismpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Wintrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"H\u00f6velmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"10389_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehad195","volume":"195","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 195. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195. (Epub ahead of print. PMID: 37622666)","journal-title":"Eur Heart J"},{"issue":"42","key":"10389_CR2","first-page":"3599","volume":"2021","author":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021(42):3599\u20133726","journal-title":"Eur Heart J"},{"key":"10389_CR3","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145:e895\u2013e1032","journal-title":"Circulation"},{"issue":"Suppl C","key":"10389_CR4","doi-asserted-by":"publisher","first-page":"C271","DOI":"10.1093\/eurheartjsupp\/suad026","volume":"25","author":"ALM Parlati","year":"2023","unstructured":"Parlati ALM, Basile C, Perrone-Filardi P (2023) Management of heart failure: similarities and discrepancies between the European Society of Cardiology and the American Heart Association guidelines. Eur Heart J Suppl 25(Suppl C):C271\u2013C275. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad026. Published 2023 Apr 26","journal-title":"Eur Heart J Suppl"},{"issue":"27","key":"10389_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128. (Epub 2016 May 20. Erratum in: Eur Heart J 2016 Dec 30; PMID: 27206819)","journal-title":"Eur Heart J"},{"key":"10389_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, B\u011blohl\u00e1vek J, B\u00f6hm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonz\u00e0lez-Medina A, Hag\u00e8ge AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan \u00d6, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators and Coordinators (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54\u201361","journal-title":"Circulation"},{"key":"10389_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"10389_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424","journal-title":"N Engl J Med"},{"key":"10389_CR9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.jacc.2021.08.064","volume":"78","author":"VN Rao","year":"2021","unstructured":"Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld J, McGuire DK, Nassif ME, O\u2019Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ (2021) In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol 78:2004\u20132012","journal-title":"J Am Coll Cardiol"},{"key":"10389_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14197","author":"A Abdin","year":"2022","unstructured":"Abdin A, Bauersachs J, Soltani S, Eden M, Frey N, B\u00f6hm M (2022) A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.14197","journal-title":"ESC Heart Fail"},{"key":"10389_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/ejhf.838","volume":"19","author":"S Zaman","year":"2017","unstructured":"Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, Cole GD (2017) The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 19:1401\u20131409","journal-title":"Eur J Heart Fail"},{"key":"10389_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00392-022-02124-w","volume":"112","author":"M Fu","year":"2023","unstructured":"Fu M, Pivodic A, K\u00e4ck O et al (2023) Real-world comparative effectiveness of ARNI versus ACEi\/ARB in HF with reduced or mildly reduced ejection fraction. Clin Res Cardiol 112:167\u2013174. https:\/\/doi.org\/10.1007\/s00392-022-02124-w","journal-title":"Clin Res Cardiol"},{"key":"10389_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396:121\u2013128","journal-title":"Lancet"},{"key":"10389_CR14","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","volume":"8","author":"J Tromp","year":"2020","unstructured":"Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, Tay WT, Dickstein K, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Lam CSP, Filippatos G, Collins SP (2020) Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health 8:e411\u2013e422","journal-title":"Lancet Glob Health"},{"key":"10389_CR15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.110.954388","volume":"123","author":"BA Borlaug","year":"2011","unstructured":"Borlaug BA, Redfield MM (2011) Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123:2006\u20132013","journal-title":"Circulation"},{"key":"10389_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00392-022-02053-8","volume":"112","author":"S Straw","year":"2023","unstructured":"Straw S, Cole CA, McGinlay M et al (2023) Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. Clin Res Cardiol 112:111\u2013122. https:\/\/doi.org\/10.1007\/s00392-022-02053-8","journal-title":"Clin Res Cardiol"},{"key":"10389_CR17","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/eurheartj\/ehaa281","volume":"41","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Bewarder Y, Kindermann I (2020) Ejection fraction in heart failure revisited- where does the evidence start? Eur Heart J 41:2363\u20132365","journal-title":"Eur Heart J"},{"key":"10389_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, B\u00f6hm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferovi\u0107 P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S (2021) Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23:352\u2013380","journal-title":"Eur J Heart Fail"},{"key":"10389_CR19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Investigators (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"10389_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, DELIVER Trial Committees and Investigators (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098","journal-title":"N Engl J Med"},{"key":"10389_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, B\u00f6hm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Pi\u00f1a IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial. Circulation 145:184\u2013193","journal-title":"Circulation"},{"key":"10389_CR22","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, K\u00f8ber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28:1956\u20131964","journal-title":"Nat Med"},{"key":"10389_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ejhf.2420","volume":"24","author":"J Butler","year":"2022","unstructured":"Butler J, Siddiqi TJ, Filippatos G, Ferreira JP, Pocock SJ, Zannad F, Anker SD (2022) Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. Eur J Heart Fail 24:245\u2013248","journal-title":"Eur J Heart Fail"},{"key":"10389_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","volume":"7","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD (2022) Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 7:1259\u20131263","journal-title":"JAMA Cardiol"},{"key":"10389_CR25","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/CIRCULATIONAHA.121.058929","volume":"145","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Claggett BL, Inciardi RM, Fonarow GC, McMurray JJV, Solomon SD (2022) Estimating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction. Circulation 145:1741\u20131743","journal-title":"Circulation"},{"issue":"17","key":"10389_CR26","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, D\u00fcngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655. (Epub 2019 Sep 1. PMID: 31475794)","journal-title":"N Engl J Med"},{"issue":"23","key":"10389_CR27","doi-asserted-by":"publisher","first-page":"00040","DOI":"10.1016\/j.cardfail.2023.02.001","volume":"1071\u20139164","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, Sharma K, Solomon SD, Starling RC, Velazquez EJ, Williamson K, Zieroth S, Braunwald E (2023) Rationale, design and baseline characteristics of the PARAGLIDE-HF Trial: sacubitril\/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event. J Card Fail 1071\u20139164(23):00040\u20134. https:\/\/doi.org\/10.1016\/j.cardfail.2023.02.001. (Epub ahead of print. PMID: 36796671)","journal-title":"J Card Fail"},{"key":"10389_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehad344","volume":"344","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, MD MPH and others (2023) Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J ehad344. https:\/\/doi.org\/10.1093\/eurheartj\/ehad344","journal-title":"Eur Heart J"},{"key":"10389_CR29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","volume":"34","author":"EA Jankowska","year":"2013","unstructured":"Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34:816\u2013829","journal-title":"Eur Heart J"},{"key":"10389_CR30","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, G\u00f6hring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF Investigators (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904 (Epub ahead of print. PMID: 36796671)","journal-title":"Lancet"},{"key":"10389_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00392-021-01837-8","volume":"110","author":"FJ Graham","year":"2021","unstructured":"Graham FJ, Pellicori P, Ford I et al (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol 110:1299\u20131307. https:\/\/doi.org\/10.1007\/s00392-021-01837-8","journal-title":"Clin Res Cardiol"},{"key":"10389_CR32","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2023","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, IRONMAN Study Group (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199\u20132209","journal-title":"Lancet"},{"issue":"2","key":"10389_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ehf2.14310","volume":"10","author":"HM Salah","year":"2023","unstructured":"Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M (2023) Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail 10(2):1473\u20131480","journal-title":"ESC Heart Fail"},{"key":"10389_CR34","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/ejhf.2338","volume":"23","author":"PM Becher","year":"2021","unstructured":"Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlstr\u00f6m U, Rosano GMC, Jankowska EA, Anker SD, Lund LH, Savarese G (2021) Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail 23:1844\u20131854","journal-title":"Eur J Heart Fail"},{"key":"10389_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11897-010-0045-1","volume":"8","author":"V Mitrovic","year":"2011","unstructured":"Mitrovic V, Jovanovic A, Lehinant S (2011) Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep 8:38\u201344","journal-title":"Curr Heart Fail Rep"},{"key":"10389_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O\u2019Connor CM, VICTORIA Study Group (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883\u20131893","journal-title":"N Engl J Med"},{"issue":"6","key":"10389_CR37","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/ehf2.14050","volume":"9","author":"M Senni","year":"2022","unstructured":"Senni M, Lopez-Sendon J, Cohen-Solal A, Ponikowski P, Nkulikiyinka R, Freitas C, Vlajnic VM, Roessig L, Pieske B (2022) Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail 9(6):3791\u20133803. https:\/\/doi.org\/10.1002\/ehf2.14050. (Epub 2022 Jul 26. PMID: 35880474; PMCID: PMC9773767)","journal-title":"ESC Heart Fail"},{"key":"10389_CR38","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJ et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895\u20132903","journal-title":"Lancet"},{"key":"10389_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-S\u00f8rensen T, B\u00f6hm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstr\u00f6m U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O\u2019Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE, GALACTIC-HF Investigators (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384:105\u2013116","journal-title":"N Engl J Med"},{"key":"10389_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","volume":"7","author":"GM Felker","year":"2022","unstructured":"Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlstr\u00f6m U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcs\u00e1nyi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol 7:26\u201333","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10389_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2022.11016","volume":"328","author":"GD Lewis","year":"2022","unstructured":"Lewis GD, Voors AA, Cohen-Solal A et al (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA 328(3):259\u2013269","journal-title":"JAMA"},{"issue":"2","key":"10389_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial Investigators (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183. (Epub 2020 Nov 16. PMID: 33200892)","journal-title":"N Engl J Med."},{"key":"10389_CR43","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00392-021-01913-z","volume":"111","author":"T T\u00e4ger","year":"2022","unstructured":"T\u00e4ger T, Frankenstein L, Atar D et al (2022) Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clin Res Cardiol 111:428\u2013439. https:\/\/doi.org\/10.1007\/s00392-021-01913-z","journal-title":"Clin Res Cardiol"},{"key":"10389_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00392-022-02076-1","volume":"112","author":"EM Screever","year":"2023","unstructured":"Screever EM, van der Wal MHL, van Veldhuisen DJ et al (2023) Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol 112:123\u2013133. https:\/\/doi.org\/10.1007\/s00392-022-02076-1","journal-title":"Clin Res Cardiol"},{"key":"10389_CR45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","volume":"271","author":"KW Streng","year":"2018","unstructured":"Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA (2018) Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 271:132\u2013139","journal-title":"Int J Cardiol"},{"key":"10389_CR46","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","volume":"7","author":"AS Desai","year":"2022","unstructured":"Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol 7:1227\u20131234","journal-title":"JAMA Cardiol"},{"key":"10389_CR47","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jchf.2017.09.010","volume":"5","author":"M B\u00f6hm","year":"2017","unstructured":"B\u00f6hm M, Ewen S (2017) Blood pressure risk associations in heart failure: true effects or inverse causality? JACC Heart Fail 5:820\u2013822","journal-title":"JACC Heart Fail"},{"key":"10389_CR48","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","volume":"38","author":"M B\u00f6hm","year":"2017","unstructured":"B\u00f6hm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38:1132\u20131143","journal-title":"Eur Heart J"},{"key":"10389_CR49","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","volume":"41","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, B\u00f6hm M, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sj\u00f6strand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 41:3402\u20133418","journal-title":"Eur Heart J"},{"key":"10389_CR50","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","volume":"78","author":"M B\u00f6hm","year":"2021","unstructured":"B\u00f6hm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Sch\u00fcler E, Ponikowski P, Wanner C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. J Am Coll Cardiol 78:1337\u20131348","journal-title":"J Am Coll Cardiol"},{"key":"10389_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac693","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm M, Anker S, Mahfoud F, Lauder L, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Saloustros I, Sch\u00fcler E, Wanner C, Zannad F, Packer M, Butler J (2022) Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac693","journal-title":"Eur Heart J"},{"key":"10389_CR52","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00392-020-01790-y","volume":"110","author":"X Chen","year":"2021","unstructured":"Chen X, Cui X, Thunstr\u00f6m E et al (2021) Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction. Clin Res Cardiol 110:1051\u20131062. https:\/\/doi.org\/10.1007\/s00392-020-01790-y","journal-title":"Clin Res Cardiol"},{"key":"10389_CR53","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ejhf.2483","volume":"24","author":"D Stolfo","year":"2022","unstructured":"Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, Hage C, Dahlstr\u00f6m U, Sinagra G, Savarese G (2022) Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 24:1047\u20131062","journal-title":"Eur J Heart Fail"},{"key":"10389_CR54","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00392-020-01792-w","volume":"110","author":"S Sze","year":"2021","unstructured":"Sze S, Pellicori P, Zhang J et al (2021) Effect of frailty on treatment, hospitalisation and death in patients with chronic heart failure. Clin Res Cardiol 110:1249\u20131258. https:\/\/doi.org\/10.1007\/s00392-020-01792-w","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10389_CR55","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","volume":"74","author":"J Tromp","year":"2019","unstructured":"Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, K\u00f8ber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV (2019) Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 74(5):601\u2013612. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.052. (PMID: 31370950)","journal-title":"J Am Coll Cardiol"},{"key":"10389_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","volume":"80","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD, EMPEROR-Preserved Trial Committees and Investigators (2022) Empagliflozin improves outcomes in patients with heart preserved left ventricular ejection fraction and preserved ejection fraction irrespective of age. J Am Coll Cardiol 80:1\u201318","journal-title":"J Am Coll Cardiol"},{"key":"10389_CR57","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ejhf.2517","volume":"24","author":"P Pellicori","year":"2022","unstructured":"Pellicori P, Cleland JGF (2022) Heart failure: age is no excuse for complacency. Eur J Heart Fail 24:1063\u20131065","journal-title":"Eur J Heart Fail"},{"key":"10389_CR58","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","volume":"118","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ (2023) Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 118:3434\u20133450","journal-title":"Cardiovasc Res"},{"key":"10389_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA (2017) Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136:6\u201319","journal-title":"Circulation"},{"key":"10389_CR60","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.mayocp.2018.11.037","volume":"94","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV, Lewis GD, Shah SJ et al (2019) Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc 94:1199\u20131209","journal-title":"Mayo Clin Proc"},{"issue":"8 Pt 1","key":"10389_CR61","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","volume":"11","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, M\u00f8ller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC (2023) Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail 11(8 Pt 1):1000\u20131010. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.010. (Epub 2023 May 21 PMID: 37294245)","journal-title":"JACC Heart Fail"},{"key":"10389_CR62","first-page":"678","volume":"7","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV, Anantha-Narayanan M, Obokata M et al (2019) Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. J Am Coll Cardiol HF 7:678\u2013687","journal-title":"J Am Coll Cardiol HF"},{"issue":"12","key":"10389_CR63","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389(12):1069\u20131084","journal-title":"N Engl J Med"},{"key":"10389_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","volume":"78","author":"RB Patel","year":"2021","unstructured":"Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M (2021) Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 78:330\u2013343","journal-title":"J Am Coll Cardiol"},{"key":"10389_CR65","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","volume":"140","author":"K Kidokoro","year":"2019","unstructured":"Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N (2019) Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140:303\u2013315","journal-title":"Circulation"},{"key":"10389_CR66","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, B\u00f6hm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O\u2019Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sj\u00f6strand M, McMurray JJV (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143:298\u2013309","journal-title":"Circulation"},{"key":"10389_CR67","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","volume":"146","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, Green JB, Rosenstock J, Schnaidt S, Brueckmann M, Pocock SJ, Packer M, Anker SD, EMPEROR-Preserved Trial Committees and Investigators (2022) Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 146:676\u2013686","journal-title":"Circulation"},{"key":"10389_CR68","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A (2021) Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99:750\u2013762","journal-title":"Kidney Int"},{"key":"10389_CR69","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","volume":"146","author":"C Adamson","year":"2022","unstructured":"Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sj\u00f6strand M, Vaduganathan M, Jhund PS, McMurray JJV (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146:438\u2013449","journal-title":"Circulation"},{"key":"10389_CR70","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"10389_CR71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","author":"WG Herrington","year":"2022","unstructured":"EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"10389_CR72","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179:3220\u20133234","journal-title":"Br J Pharmacol"},{"key":"10389_CR73","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219\u20132229","journal-title":"N Engl J Med"},{"key":"10389_CR74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, FIGARO-DKD Investigators et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"10389_CR75","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474\u2013484","journal-title":"Eur Heart J"},{"issue":"41","key":"10389_CR76","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401.PMID:35900838;PMCID:PMC9622299","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, Friede T, Fabien V, Kosiborod M, Metra M, Pi\u00f1a IL, Pinto F, Rossignol P, van der Meer P, Bahit C, Belohlavek J, B\u00f6hm M, Brugts JJ, Cleland JGF, Ezekowitz J, Bayes-Genis A, Gotsman I, Goudev A, Khintibidze I, Lindenfeld J, Mentz RJ, Merkely B, Montes EC, Mullens W, Nicolau JC, Parkhomenko A, Ponikowski P, Seferovic PM, Senni M, Shlyakhto E, Cohen-Solal A, Szecs\u00f6dy P, Jensen K, Dorigotti F, Weir MR, Pitt B (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362\u20134373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401.PMID:35900838;PMCID:PMC9622299","journal-title":"Eur Heart J"},{"issue":"10","key":"10389_CR77","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1214234","volume":"369","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Matsushita K, \u00c4rnl\u00f6v J et al (2013) Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369(10):932\u2013943","journal-title":"N Engl J Med"},{"issue":"5","key":"10389_CR78","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.ajkd.2023.03.005","volume":"82","author":"A Pinsino","year":"2023","unstructured":"Pinsino A, Carey MR, Husain S et al (2023) The difference between cystatin C- and creatinine-based estimated GFR in heart failure with reduced ejection fraction: insights from PARADIGM-HF. Am J Kidney Dis 82(5):521\u2013533","journal-title":"Am J Kidney Dis"},{"key":"10389_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000313718","volume":"164","author":"C Ronco","year":"2010","unstructured":"Ronco C (2010) Cardiorenal syndromes: definition and classification. Contrib Nephrol 164:33\u201338","journal-title":"Contrib Nephrol"},{"key":"10389_CR80","first-page":"71","volume":"16","author":"GS Braun","year":"2021","unstructured":"Braun GS, Kittelmann K, Floege J (2021) Akute Nierensch\u00e4digung bei kardiorenalem Syndrom Nephrologe 16:71\u201380","journal-title":"Akute Nierensch\u00e4digung bei kardiorenalem Syndrom Nephrologe"},{"key":"10389_CR81","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00392-020-01779-7","volume":"110","author":"J Simonavi\u010dius","year":"2021","unstructured":"Simonavi\u010dius J, Maeder MT, Eurlings CGMJ et al (2021) Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF. Clin Res Cardiol 110:1221\u20131233. https:\/\/doi.org\/10.1007\/s00392-020-01779-7","journal-title":"Clin Res Cardiol"},{"key":"10389_CR82","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jchf.2020.03.009","volume":"8","author":"W McCallum","year":"2020","unstructured":"McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ (2020) Acute kidney function declines in the context of decongestion in acute decompensated heart failure. JACC Heart Fail 8:537\u2013547","journal-title":"JACC Heart Fail"},{"key":"10389_CR83","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M, ADVOR Study Group (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387:1185\u20131195","journal-title":"N Engl J Med"},{"key":"10389_CR84","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","volume":"146","author":"PC Schulze","year":"2022","unstructured":"Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, von Haehling S, Schumacher U, M\u00f6bius-Winkler S, Busch M (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146:289\u2013298","journal-title":"Circulation"},{"key":"10389_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-022-02148-2","author":"PEP Carvalho","year":"2023","unstructured":"Carvalho PEP, Veiga TMA, Sim\u00f5es e Silva AC et al (2023) Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-022-02148-2","journal-title":"Clin Res Cardiol"},{"key":"10389_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac689","author":"JC Trull\u00e0s","year":"2022","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, S\u00e1nchez-Marteles M, Conde-Martel A, D\u00e1vila-Ramos MF, Ll\u00e1cer P, Salamanca-Bautista P, P\u00e9rez-Silvestre J, Plas\u00edn M\u00c1, Cerqueiro JM, Gil P, Formiga F, Manzano L, CLOROTIC trial investigators (2022) Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac689","journal-title":"Eur Heart J"},{"key":"10389_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14157","author":"S Odajima","year":"2022","unstructured":"Odajima S, Fujimoto W, Kuroda K, Yamashita S, Imanishi J, Iwasaki M, Todoroki T, Okuda M, Hayashi T, Konishi A, Shinohara M, Toh R, Hirata KI, Tanaka H (2022) Association of congestion with worsening renal function in acute decompensated heart failure according to age. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.14157","journal-title":"ESC Heart Fail"},{"key":"10389_CR88","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ejhf.1492","volume":"21","author":"O Chioncel","year":"2019","unstructured":"Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH, ESC-EORP-HFA Heart Failure Long-Term Registry Investigators (2019) Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 21:1338\u20131352","journal-title":"Eur J Heart Fail"},{"key":"10389_CR89","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28:568\u2013574","journal-title":"Nat Med"},{"key":"10389_CR90","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1002\/ehf2.13391","volume":"8","author":"R Matsukawa","year":"2021","unstructured":"Matsukawa R, Masuda S, Matsuura H, Nakashima H, Ikuta H, Okabe K, Okahara A, Kawai S, Tokutome M, Tobushi T, Mukai Y (2021) Early follow-up at outpatient care after discharge improves long-term heart failure readmission rate and prognosis. ESC Heart Fail 8:3002\u20133013","journal-title":"ESC Heart Fail"},{"key":"10389_CR91","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938\u20131952","journal-title":"Lancet"},{"issue":"19","key":"10389_CR92","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","volume":"73","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Fonarow GC, DeVore AD et al (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365\u20132383","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10389-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T09:15:37Z","timestamp":1713777337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10389-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":92,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["10389"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10389-8","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"30 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"J.W. and M.B. are supported by the Deutsche Forschungsgemeinschaft. J.W. is supported by Deutsche Herzstiftung and has received lecture honoraria from Bristol Myers Squibb. M.B. reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis, Servier, and Vifor. All other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}